Literature DB >> 35537731

Evidence-based exercises intervention in adults diagnosed with Lymphoma.

Amani A AlJohi1, Ghaidaa H Aljehani1, Safanah A AlSaeed1, Hind Alhoqail1, Jaleel Mohammed1, Sanaa M Madi1.   

Abstract

OBJECTIVES: To evaluate the efficacy of physical therapy or exercise intervention on quality of life (QOL), fatigue, sleep, and psychological and physical functioning in adults diagnosed with Lymphoma.
METHODS: A systematic literature search of the PubMed, CINAHL, Cochrane Library, and PEDro databases was carried out to identify articles published from March 2010 until December 2020. The risk of bias, methodological quality, and level of evidence was evaluated using the Physiotherapy Evidence Database (PEDro) checklist.
RESULTS: Out of the 577 articles identified from the initial search, a total of 12 randomised control trials were shortlistd for this systematic review. From the 12 articles, 9 studies included participants with Lymphoma who were at various stages of chemotherapy or had completed treatment and 3 studies included participants with various haematological malignancies and had stem cell transplantation. The quality of each study was assessed using the PEDro scale with the a mean score of 6.3±0.89. The PEDro scores regarding the quality of studies ranged from 5-8 (fair to good).
CONCLUSION: There is moderate evidence strength suggesting that exercises therapy for persons diagnosed with Lymphoma can include aerobic or cardiovascular exercise, strength training, and mind-body exercise has beneficial effects on fatigue, physical performance, and QOL in persons diagnosed with Lymphoma patients.PROSPERO No.: CRD42021227418. Copyright: © Saudi Medical Journal.

Entities:  

Keywords:  Lymphoma; exercise; physical therapy; systematic review

Mesh:

Year:  2022        PMID: 35537731      PMCID: PMC9280599          DOI: 10.15537/smj.2022.43.5.20210894

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.422


Lymphoma patients can suffer from poor quality of life (QOL) and reduced functional capacity because of the disease or treatment-related complications. Lymphoma, defined as malignant neoplasms of lymphoid origin, can be broadly classified into 2 main categories: Hodgkin Lymphoma (HL; prevalence-10%) and non-Hodgkin Lymphoma (NHL; prevalence-90%).1 Hodgkin Lymphoma is an uncommon B-cell Lymphoma, which accounted for 83,087 new registered cases and 23,376 deaths, whereas 544,352 new cases of NHL were registered with 259,793 deaths globally in the year 2018.2 The prevalence of HL has been reported to be higher in the age group of 20-39 years, whereas NHL is more prevalent in patients ≥60 years of age. Lymphoma is believed to be more common among males than in females. In addition, male patients display increased mortality rates and the risk is 3.1-fold and 1.7-fold higher among individuals with a family history of HL and NHL. Depending on the type of Lymphoma, the treatment protocol can involve active surveillance of the condition, chemotherapy, radiation therapy, and autologous or allogeneic stem cell transplants. Patients diagnosed with Lymphoma who undergo therapeutic interventions for the management of HL and NHL are often imperilled to several systemic and non-systemic complications. Cardiac or pulmonary complications, and risk of infections are some of the common complications observed in patients diagnosed with Lymphoma. Lymphoma survivors usually suffer from diminished physical capacity, cardiopulmonary compromise, reduced muscle power, and limited physical function during and after treatment and the survivorship related complications can last for up to 10 years. Physical therapy (PT) intervention has been advocated as a part of the multidisciplinary approach to help improve QOL and physical function. However, the PT intervention mostly depends on the treatment regime, associated complications, and its impact on patients’ function, thereby making it challenging for the rehabilitation specialists. A recent systematic review reported positive outcomes from aerobic endurance training, sensorimotor, and strength training on patients fatigue, psychological symptoms, and QOL. Mind-body exercises, such as yoga and Chan-Chuang qigong, have also been reported as having favorable effects on fatigue, general QOL, and sleep pattern. However, there are concerns regarding the study design and quality of trials; and hence the current systematic review aim is to evaluate the overall effectiveness of PT intervention on QOL, fatigue, sleep, and psychological and physical function in adults diagnosed and treated for Lymphoma.

Methods

The current systematic review was carried out in accordance with the guidelines of the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. A literature search was carried out to cover the period between April to June 2020. Additionally, the literature search was regularly updated during the review and writing process (July to December 2020). A comprehensive, electronic literature search was carried out using the following databases: PubMed, Cumulative Index of Nursing and Allied Health Literature (CINAHL), Physiotherapy Evidence Database (PEDro), and Cochrane Library. The search strategy involved the use of several keywords and Medical Subject Headings (MeSH) terms. The Boolean operators “and” and “or” were used to combine the search terms. Moreover, thesaurus terms and relevant truncation or wildcard symbols were used to retrieve all possible suffix variations of a root word. Initially, the search was carried out using every single keyword. In the second step, the keywords were combined in pairs and trios, and finally, a conclusive search was carried out using a combination of all the keywords. All the electronic searches were limited to full-text, peer-reviewed publications in English involving human adults. The electronic search was carried out to identify articles published from March 2010 to March 2020. Duplicate studies from separate databases were eliminated. The detailed list of keywords and search strategies employed to perform the literature search of electronic databases are presented in Table 1. In addition, the electronic search was supplemented by the manual inspection of the reference lists pertaining to papers included in the present review, to identify other eligible studies.
Table 1

- Keywords and searching strategy of the electronic databases.

DatabaseNo. of articles
PubMed
1Haematological cancer9603
2Non-Hodgkin lymphoma109943
3Hodgkin lymphoma75296
4Haematological malignancies43353
5Lymphoma266086
6Lymphoma or haematological malignancies or Hodgkin lymphoma or non-Hodgkin lymphoma or Haematological cancer307747
7Cancer rehabilitation33711
8Rehabilitation621523
9Physical therap86136
10Physiotherap49154
11Physical therapy modalities154132
12Home exercises12463
13Physical exercises430431
14Physical function1226213
15Physical activity552715
16Aerobic exercise426161
17Exercise426161
18Endurance38508
19Strength320906
20Strength or endurance or exercise or aerobic exercise or physical activity or physical function or physical exercises or home exercises or physical therapy modalities or physiotherap or physical therap or rehabilitation or cancer rehabilitation2276859
21Quality of life395059
22Chronic fatigue105793
23Fatigue18650
24Pain824389
25Impairments65601
26Bone health123100
27Spine metastasis4052
28Chemotherapy induced neuropathy6521
29Cardio-toxicity117
30Cardiotoxicity11778
31Bone health or cardiotoxicity or cardio-toxicity or spine metastasis or impairments or fatigue or chronic fatigue or pain or quality of life or chemotherapy induced neuropathy1426700
326 and 20 and 31996
3332 filters: published in the last 10 years; humans; English; adult: 19+ years344
Cumulated Index to Nursing and Allied Health Literature
1Haematological cancer2461
2Non-Hodgkin lymphoma6255
3Hodgkin lymphoma2920
4Haematological malignancies2276
5Lymphoma28843
6Lymphoma or haematological malignancies or Hodgkin lymphoma or non-Hodgkin lymphoma or haematological cancer32046
7Cancer rehabilitation4913
8Rehabilitation183177
9Physical therap131986
10Physiotherap22376
11Physical therapy modalities4824
12Home exercises312
13Physical exercises324
14Physical function7974
15Physical activity79573
16Aerobic exercise21258
17Exercise188792
18Endurance15238
19Strength49351
20Strength or endurance or exercise or aerobic exercise or physical activity or physical function or physical exercises or home exercises or physical therapy modalities or physiotherap or physical therap or rehabilitation or cancer rehabilitation559761
21Quality of life182158
22Chronic fatigue3133
23Fatigue52784
24Pain314617
25Impairments95347
26Impairments or fatigue or chronic fatigue or pain or quality of life591160
276 and 20 and 31299
2832 filters: published in the last 10 years; humans; English; adult127
Cochrane Library
1Rehabilitation and lymphoma2
2Rehabilitation and haematological cancer1
3Rehabilitation and non-Hodgkin lymphoma0
4Rehabilitation and Hodgkin lymphoma0
5Rehabilitation and cancer24
6Rehabilitation and haematological malignancies1
7Physical therapy and lymphoma7
8Physical therapy and haematological malignancies5
9Physical therapy and haematological cancer7
10Physical therapy and non-Hodgkin lymphoma1
11Physical therapy and cancer87
12Physical therapy and Hodgkin lymphoma1
13Physiotherapy and Haematological cancer0
14Physiotherapy and Hodgkin lymphoma0
15Physiotherapy and haematological malignancies0
16Physiotherapy and lymphoma0
17Physiotherapy and non-Hodgkin lymphoma0
18Physiotherapy and cancer6
19Exercise and lymphoma4
20Exercise and non-Hodgkin lymphoma1
21Exercise and Hodgkin lymphoma1
22Exercise and haematological cancer5
23Exercise and haematological malignancies4
24Exercise and cancer49
25Quality of life and lymphoma28
26Chronic fatigue and lymphoma0
27Fatigue and lymphoma9
28Pain and lymphoma4
29Impairments and lymphoma4
30Quality of life and haematological cancer57
31Chronic fatigue and haematological cancer1
32Fatigue and haematological cancer14
33Pain and haematological cancer12
34Impairments and haematological cancer0
35Duplication removed67
Physiotherapy Evidence Database
1Haematological cancer6
2Non-Hodgkin lymphoma5
3Hodgkin lymphoma5
4Haematological malignancies4
5Lymphoma20
6Duplication removed19
- Keywords and searching strategy of the electronic databases. Articles were included if they were full, peer-reviewed articles, written in English involving human adults, were randomized controlled trials, discussing any PT interventions, including participants >18 years of age, with a confirmed diagnosis of any type or stage of Lymphoma; and there were no demographic or ther restrictions, studies published during the time period from March 2010 to December 2020 date, owing to significant changes in the medical management of Lymphoma that would affect the incidence of adverse effects. The exclusion criteria employed by the present review were abstracts, conference reports, unpublished studies, articles published in non-peer-reviewed journals, case study, case series, single case reports, qualitative studies, trials published in languages other than English, and studies involving subjects/patients <18 years of age. Five authors (AJ, GJ, SS, HX, and JX) independently screened the titles, abstracts, and full texts of the articles (as needed) identified through the literature search against the selection criteria. The authors then agreed on and excluded the studies that failed to meet the inclusion/exclusion criteria. Full-text articles were reviewed by 3 independent reviewers (AJ, GJ, and SS). Any disagreements with regard to the selection of studies were resolved through discussions and the involvement of a fourth reviewer (SM). The process of selection and reasons for exclusion are illustrated in a PRISMA flow diagram (Figure 1).
Figure 1

- The Preferred Reporting Items for Systematic Review and Meta-analysis flowchart of the entire search and selection procedure.

- The Preferred Reporting Items for Systematic Review and Meta-analysis flowchart of the entire search and selection procedure. Three reviewers (AJ, GJ, and SS) independently completed the data extraction and tabulation of information including: authors, title, publication date, aims, participants, age, diagnoses, treatment, inclusion/exclusion criteria, study design, and level of evidence using the Sackett’s levels of evidence (type and duration of intervention, duration of follow-up, outcomes and quality assessment). The extracted data are presented in Table 2. All the entered data were manually cross-checked for discrepancies through a zoom meeting and disagreements were referred to a fourth reviewer (SM).
Table 2

- The data items extracted.

AuthorsPatients characteristicsIntervention groupControl group/UCResults
Lymphoma percentageIntervention groupControl group
Hung et al 27 37 patients undergoing autologous transplantation are recruited (lymphoma 17 [45.9], MM 20 [54.1])n=16/18 Mean age: 57.5±9.8 Male= 10 (55.6)n=17/18 Mean age: 59.9±9.2 Male= 10(52.6)All patients received best practice nutrition care. Nutrition care included: an initial nutrition assessment and counselling- There is an increase in protein consumption in home-based nutrition and exercise program comparing to UC but not Significant - IG improved in cognitive and social functioning in comparing to UC.
Zimmer et al 20 26 patients participated and 10 healthy population (NHL) after 1st line chemotherapyn=14 (5 healthy)n=12 (5 healthy)Exercising on a bicycle ergometer 30 mins at moderate intensityNo interventionInterleukin-6 was higher in the NHL patients compared with control subject, acetylation of the CD8+ T-cell histone H4K45 increased in response to the exercise.
Patients mean age: 62.23±13.09 Healthy mean age: 56.6±10.73 Patient’s gender: F=6, M=20 Healthy’s gender: F=3, M=7
Courneya et al 21 122/117 lymphoma patient were receiving chemotherapy or no treatmentsn=57/60 Mean age:18±31.6 (<50 years)39±68.4(>50 years) Male= 35 (61.4) Female= 22 (38.6)n=60/62 Mean age:20±33.3 (<50 years)40±66.7 (>50 years) Male= 34 (56.7) Female= 26 (43.3)12-weeks supervised exercise program on a cycle ergometer.Not increase their exercise from baseline.It has a significant improvement of sleep pattern in specifically patient with indolent NHL.
Streckmann et al 18 61 lymphoma newly diagnosed prior to chemotherapy (MM: 14, NHL: 32, HL: 12), total lymphoma: 44 (75.9)n=30/28 Mean age: 44 years M=20 (71)/F=8 (29)n=31/28 Mean age: 48 years M=22 (79)/F=6(21)Supervised exercise 2/36 weeks 1) Aerobic endurance training. 2) Sensorimotor training. 3) Strength training.Standard clinical care including physiotherapyIG showed a significant improvement in health-related QoL score and activity level with no change in UC.Slight improvement in PNP sensitivity in IG.
Vallerand et al 25 51 survivors; leukemia: 19 (37), NHL: 10 (20), HL: 22 (43), and total lymphoma: 32 (63)n=25n=26Participants in both groups received a copy of Canada’s Physical Activity GuidelineSatisfaction of telephone counselling sessions was high (93%) and changes in exercise behavior by increasing weekly aerobic exercise.
Mean age: 52.6±13.7<60 years: 33 (65)≥60 years:18 (35) F= 31 (61); M= 20 (39)
Telephone counselling sessionsReceived no other intervention

Values are presented as a number and (%), mean±standard deviatin (SD). AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, HL: Hodgkin lymphoma, NHL: non-Hodgkin lymphoma, IG: intervention group, UC: usual care, M: male, F: female, QOL: quality of life

- The data items extracted. Values are presented as a number and (%), mean±standard deviatin (SD). AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, HL: Hodgkin lymphoma, NHL: non-Hodgkin lymphoma, IG: intervention group, UC: usual care, M: male, F: female, QOL: quality of life - The data items extracted. Values are presented as a number and (%), mean±standard deviatin (SD). AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, HL: Hodgkin lymphoma, NHL: non-Hodgkin lymphoma, IG: intervention group, UC: usual care, M: male, F: female, QOL: quality of life

Quality assessment/appraisal

The methodological quality of the trials included in the present review was evaluated using the PEDro scale, which is a 10-item scale designed to assess the internal validity (8 items) of a trial, including randomization, concealed allocation, blinding, baseline similarity, intention to treat, and 2 items, namely, measures of key outcomes from more than 85.0% of subjects and relevant reporting of the trial’s statistical comparisons. The score for each article ranged from 0 (lowest quality) to 8 (highest quality). Scores of 4-10 denote fair to high quality and 0-3 denote poor to low quality. The methodological quality of each study was independently assessed by 3 reviewers (AJ, GJ, and SS). Disagreements among the reviewers were resolved through consensus-based discussions and the assistance of a fourth reviewer (SM) was enlisted in case of persistent disagreements. The results of the quality assessment of studies are presented in Table 3.
Table 3

- The results of the quality assessment of the included intervention studies.

Quality assessmentCorresponding & authors
Hung et al 27 Zimmer et al 20 Courneya et al 22 Streckmann et al 18 Vallerand et al 25 Persoon et al 28 Furzer et al 24 Chuang et al 17 Van Dongen et al 26 Yeh et al 19 Courneya et al 21 Courneya et al 23
Eligibility criteria were specifiedYesYesYesYesYesYesYesYesYesYesYesYes
Subjects were randomly allocated to groups (in a crossover study, subjects were randomly allocated an order in which treatments were received)YesYesYesYesYesYesYesYesYesYesYesYes
Allocation was concealedYesNoYesNoYesYesNoYesYesYesYesYes
The groups were similar at baseline regarding the most important prognostic indicatorsYesYesYesYesYesYesYesYesYesYesYesYes
There was blinding of all subjectsNoNoNoNoNoNoNoNoNoNoNoNo
There was blinding of all therapists who administered the therapyNoNoNoNoNoNoNoNoNoNoNoNo
There was blinding of all assessors who measured at least one key outcomeNoNoNoYesNoYesNoNoNoNoNoNo
Measures of at least one key outcome were obtained from more than 85% of the subjects initially allocated to groupsYesYesYesYesYesYesNoYesNoYesYesYes
All subjects for whom outcome measures were available received the treatment or control condition as allocated or, where this was not the case, data for at least one key outcome was analysed by “intention to treat”NoNoYesYesYesYesYesNoYesNoYesYes
The results of between-group statistical comparisons are reported for at least one key outcomeYesYesYesYesYesYesYesYesYesYesYesYes
The study provides both point measures and measures of variability for at least one key outcomeYesYesYesYesYesYesYesYesYesYesYesYes
Total score6/105/107/107/107/108/105/106/106/106/107/107/10
Level of evidence (based on Sackett)1b2b1b1b1b1b2b1b1b1b1b1b
- The results of the quality assessment of the included intervention studies.

Evidence assessment

The current review employed the system developed by the Oxford Centre for Evidence-based Medicine to grade the levels of evidence, in order to determine the degree of confidence concerning the evidence regarding an intervention. The mentioned scale has 5 levels, ranging from 1a (well-designed meta-analysis or high-quality RCTs) to 5 (no well-designed studies). Each study was independently assessed by 3 reviewers (AJ, GJ, and SS), in accordance with Sackett’s levels of evidence.

Results

The systematic literature search yielded 577 results (PubMed: 344; CINAHL: 27; Cochrane Library: 67; and PEDro: 19). Subsequently, duplicate publications were excluded and 408 articles were retained for review, among which, 12 articles met the inclusion criteria. The PRISMA flowchart of the search and selection procedure is shown in Figure 1. The current review included 12 randomized controlled trials that involved 1010 participants, among which, 824 were diagnosed with Lymphoma. The sample size ranged from 36-122 and age of the participants ranged from 19-90 years. Out of the 577 articles identified from the initial search, a total of 12 randomised control trials were shortlistd for this systematic review. From the 12 articles, 9 studies included participants with Lymphoma who were at various stages of chemotherapy or had completed treatment and 3 studies included participants with various haematological malignancies and had stem cell transplantation.

Quality of the studies

Physiotherapy Evidence Database scale was used for assessing the quality of the studies and the mean PEDro score for the 12 RCTs was 6.3±0.89. Detailed information regarding the PEDro scores pertaining to the studies is presented in Table 3. The data presented in Table 3 shows that all the studies exhibited a baseline similarity, reported statistical comparisons, were randomly assigned, and provided both point measures and measures of variability. However, none of the trials complied with the items of blinding and was considered to have a high risk of bias with reference to blinding the subjects, therapists, and assessors, except for the study by Persoon et al, which involved a low risk of bias associated with blinding the assessors alone. In addition, all the studies stated that the allocation was concealed, except 3 studies. Additionally, 4 trials included in the present review did not comply with the item of intention to treat. Furthermore, details regarding the grading of levels of evidence using the system developed by the Oxford Centre for Evidence-based Medicine are presented in Table 3. Most of the studies (10/12) were assigned with the grade of 1b (high-quality RCTs), whereas 2 studies were assigned with the grade of 2b (limited non-randomized trials). Overall, the studies displayed reliable methodological quality, indicating a low risk of bias.

Interventions

The primary PT intervention was exercise and included aerobic exercises, resistance exercises, balance exercises, education, and mind-body exercises. Two studies used telephone consultations as the primary intervention. The mean duration of the exercise interventions varied from 3-36 weeks, and majority of the studies used moderate-to high-intensity aerobic exercises with 50-85% of peak oxygen consumption or heart rate max. The range of resistive exercise intensity was 50±80% of the indirectly determined one-repetition maximum. The mean frequency of exercise interventions varied from once to daily per week for 15-60 minutes.

Multiple outcomes measures

The studies included in the current review, evaluated subjective and patient-reported outcomes concerning several variables, including the QOL, fatigue, psychological wellbeing, monitored side-effects, sleep pattern, and lifestyle (physical activity and nutritional status). Five trials assessed CV fitness whereas 3 other stuides assessed the muscle strength of the upper and lower limbs. Streckmann et al evaluated the balance and peripheral deep sensitivity.

Discussion

This systematic review, showed that PT treatment programs and individualized exercises for different Lymphoma stages significantly improved physical function and endurance. Studies showed various exercise programs and PT interventions have been tested for those patients to assess the improvement of patients’ outcomes. The current review aimed to assess the available evidence regarding the effectiveness of PT or exercise intervention in adults diagnosed with Lymphoma with reference to the improvements in QOL, fatigue, sleep, and psychological and physical function. The literature review yielded 12 randomized controlled trials (RCTs) of varying methodological quality and sample sizes, which displayed considerable variation with regard to the inclusion criteria concerning diagnosis. Vallerand et al included leukemia and Lymphoma patients, 5 studies included Lymphoma and multiple myeloma patients and 6 studies included Lymphoma patients alone. Moreover, the baseline characteristics of the patients diagnosed with Lymphoma ranged from newly diagnosed cases to long-term survivors, which increased the likelihood of heterogeneity and made the interpretation and comparison of results difficult. Furthermore, the studies displayed considerable variation with reference to the PT interventions, including aerobic training, strength training, sensorimotor training, strength training, home-based exercise, telephone counseling sessions, and other intervention with mind-body exercise. In addition, the current review observed variations in the frequency, intensity, and duration of interventions across the studies. Consequently, the determination of a standardized intervention protocol for clinical practice was challenging. An additional, significant constituent of the current objectives and practice of PT is the assessment of the carryover effect. The present review included only one longitudinal study that reported the results of a one-year follow-up. Consequently, the long-term effects and the ability of Lymphoma patients to maintain the beneficial effects of the interventions remain ambiguous. A majority of the studies did not comply with the criteria of blinding the patients, therapists, or assessors. In the current review, only Persoon et al described the blinding methods employed. Although blinding the patients, therapists, or assessors is an effective method that can be employed to control the confounding variables in RCTs, the implementation may not always be possible. Although blinding may be initially possible in many studies, the maintenance of the same throughout a trial might become challenging. A major cause of missing data in clinical trials is the dropout/withdrawal of subjects, which creates uncertainty in relation to the interpretation of results. Dropout of subjects is also an important outcome, as it may reflect the lack of tolerance to interventions, adverse effects, or lack of compliance. Among the 12 studies, 10 discussed the dropout/withdrawal status of their respective subjects. Moreover, it is important to take note of the occurrence of any adverse events during the intervention. In the current review, 8 studies addressed the incidence of adverse events. Several standardized tools have been used to evaluate the outcomes of PT interventions in persons diagnosed with Lymphoma. Eight studies used QOL to assess the outcomes of interventions. Furthermore, 4 trials assessed CV fitness. Two reported significant improvements in physical performance and 3 trials assessed the muscle strength in the upper and lower limbs. The current review used stringent inclusion criteria and a narrow population to reduce some of the inconsistencies that bulge the current body of literature. It provides high-quality evidence-based practice to determine whether the PT intervention is an effective and safe intervention for adult patients with Lymphoma.

Study limitations

First, the review may not offer a comprehensive picture of the available evidence, because of the fact that the review was limited to English articles. Consequently, there is a possibility that good-quality studies written in other languages, which might have supported the present recommendations, were excluded. The statistical heterogeneity among the studies included in the review was another limitation. Potential sources of heterogeneity include variations in the type, duration, and intensity of interventions. Moreover, the initiation of PT interventions varied across the studies. Hence, the results of the current review must be interpreted with caution, owing to the baseline differences and heterogeneity of the study population. Future research warrants RCTs with larger samples and long-term follow-ups, in order to improve the understanding of the effects of PT interventions and exercise on Lymphoma patients. In conclusion, there is moderate evidence strength suggesting that exercises therapy for persons diagnosed with Lymphoma can include aerobic or CV exercise, strength training, and mind-body exercise has beneficial effects on fatigue, physical performance, and QOL in persons diagnosed with Lymphoma patients. Future research should focus on more robust and well-defined exercises therapy intervention protocols, in order to establish the long-term benefit of exercises therapy intervention.
Table 2

- The data items extracted.

AuthorsPatients characteristicsIntervention groupControl group/UCResults
Lymphoma percentageIntervention groupControl group
Van Dongen et al 26 109 participants recently treated with autologous stem cell transplantation (MM: 58 (53.2) or lymphoma: 51 (46.8)n=54/48 Mean age: 53.5±20.67 M= 32 (59)n=55/45 Mean age: 56±19.67 M= 37 (67)18-weeks High-intensity resistance and interval training ex’s.No exercise intervention86% patients showed up in average of 10 sessions of supervised exercise in IG. Result showed up to 25% improvement in physical fitness. Fatigue level was improved in both groups with no different.
Furzer et al 24 37 haematological cancer having completed treatment (NHL: 27 (73), HL: 6 (16), MM: 4 (11)n=18 Mean age: 48.2±12.3 (range: 22-64)n=19 Mean age: 49.6±14.1 (range: 25-68)12 weeks tailored exercise intervention which includes progressed cardiovascular training and resistance program.Did not complete any structured exercise.Provided diary & general healthy life-style adviceThe physiological outcomes showed a significant improvement in: cancer related fatigue, cardiovascular fitness, QoL, and body composition.
Chuang et al 17 96 NHL patients who underwent their first course of chemotherapyn=48 Mean age: 55.85±16.78 M= 26 (27.1) F= 22 (22.9)n=48 Mean age: 64.54±15.51 M= 29 (30.2) F= 19 (19.8)A Chan-Chuang Qigong program for 21 days.The nursing guidance booklet is modified and tailored to patients with NHLNo interventionIt showed significant decreased in fatigue intensity and interference in the qigong group. Also, improvement in the IG in white blood cell counts, hemoglobin levels, sleep quality, and QOL.
Yeh et al 19 108 non-Hodgkin’s lymphoma patients who were undergoing chemotherapy (1st cycle chemotherapy)n=51 M= 28 (54.9) F= 23 (45.1)n=51 M= 29 (56.9) F= 22 (43.1)Chan-Chuang qigong for 21 daysUsual careThe qigong group showed a significant decreased over time in the average fatigue, worse fatigue, and overall sleep.
Mean age: 59.79±16.54 years (range 23-90 years)
Courneya et al 23 122 lymphoma receiving chemotherapy or no treatments.n=57n=60Supervised aerobic exercise program (bike).Telephone follow-up of missed sessions.Asked not to increase their exercise during the intervention.Effects of aerobic exercise on sleep quality: improvement in global sleep quality compared with UC.
Mean age: 53 years F=48 and M=69
Courneya et al 21 122 lymphoma patientsn=60 Mean age: 52.8 (range: 18-77)n=62 Mean age: 53.5 (range: 18-80)12 weeks of supervised aerobic exercise program (gradual increase intensity)Not to increase their exercise during the interventionThere was no any statistically significant associations between exercise levels and cancer-specific mortality.

Values are presented as a number and (%), mean±standard deviatin (SD). AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, HL: Hodgkin lymphoma, NHL: non-Hodgkin lymphoma, IG: intervention group, UC: usual care, M: male, F: female, QOL: quality of life

  27 in total

1.  Chemotherapy and Radiation Induced Pulmonary Dysfunction in Hodgkin Lymphoma Patients.

Authors:  Sebnem Izmir Guner; Mustafa Teoman Yanmaz; Ahmet Selvi; Cigdem Usul
Journal:  Indian J Hematol Blood Transfus       Date:  2015-11-14       Impact factor: 0.900

2.  High levels of physical activity are associated with lower levels of fatigue among lymphoma patients: Results from the longitudinal PROFILES registry.

Authors:  Olga Husson; Simone Oerlemans; Floortje Mols; Goof Schep; Lonneke V Van De Poll-Franse
Journal:  Acta Oncol       Date:  2015-03-09       Impact factor: 4.089

3.  Predictors of follow-up exercise behavior 6 months after a randomized trial of supervised exercise training in lymphoma patients.

Authors:  Kerry S Courneya; Clare Stevinson; Margaret L McNeely; Christopher M Sellar; Christine M Friedenreich; Carolyn J Peddle-McIntyre; Neil Chua; Tony Reiman
Journal:  Psychooncology       Date:  2011-07-18       Impact factor: 3.894

4.  A randomized trial of aerobic exercise and sleep quality in lymphoma patients receiving chemotherapy or no treatments.

Authors:  Kerry S Courneya; Christopher M Sellar; Linda Trinh; Cynthia C Forbes; Clare Stevinson; Margaret L McNeely; Carolyn J Peddle-McIntyre; Christine M Friedenreich; Tony Reiman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-04-20       Impact factor: 4.254

Review 5.  Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant.

Authors:  Seth J Rotz; Thomas D Ryan; Joel Hlavaty; Stephen A George; Javier El-Bietar; Christopher E Dandoy
Journal:  Pediatr Blood Cancer       Date:  2017-04-28       Impact factor: 3.167

6.  Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy.

Authors:  F Streckmann; S Kneis; J A Leifert; F T Baumann; M Kleber; G Ihorst; L Herich; V Grüssinger; A Gollhofer; H Bertz
Journal:  Ann Oncol       Date:  2014-02       Impact factor: 32.976

7.  INFECTIOUS COMPLICATIONS AS A PREDICTOR OF MORTALITY IN PATIENTS WITH NON-HODGKIN LYMPHOMA RECEIVING RITUXIMAB-CONTAINING CHEMOTHERAPY.

Authors:  Patricia Meza-Meneses; Patricia Cornejo-Juárez; Diana Vilar-Compte; Patricia Volkow-Fernández
Journal:  Rev Invest Clin       Date:  2019       Impact factor: 1.451

8.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.

Authors:  David Moher; Larissa Shamseer; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart
Journal:  Syst Rev       Date:  2015-01-01

9.  Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study.

Authors:  Saskia Persoon; Mai J M ChinAPaw; Laurien M Buffart; Roberto D K Liu; Pierre Wijermans; Harry R Koene; Monique C Minnema; Pieternella J Lugtenburg; Erik W A Marijt; Johannes Brug; Frans Nollet; Marie José Kersten
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

10.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.

Authors:  Christina Fitzmaurice; Degu Abate; Naghmeh Abbasi; Hedayat Abbastabar; Foad Abd-Allah; Omar Abdel-Rahman; Ahmed Abdelalim; Amir Abdoli; Ibrahim Abdollahpour; Abdishakur S M Abdulle; Nebiyu Dereje Abebe; Haftom Niguse Abraha; Laith Jamal Abu-Raddad; Ahmed Abualhasan; Isaac Akinkunmi Adedeji; Shailesh M Advani; Mohsen Afarideh; Mahdi Afshari; Mohammad Aghaali; Dominic Agius; Sutapa Agrawal; Ayat Ahmadi; Elham Ahmadian; Ehsan Ahmadpour; Muktar Beshir Ahmed; Mohammad Esmaeil Akbari; Tomi Akinyemiju; Ziyad Al-Aly; Assim M AlAbdulKader; Fares Alahdab; Tahiya Alam; Genet Melak Alamene; Birhan Tamene T Alemnew; Kefyalew Addis Alene; Cyrus Alinia; Vahid Alipour; Syed Mohamed Aljunid; Fatemeh Allah Bakeshei; Majid Abdulrahman Hamad Almadi; Amir Almasi-Hashiani; Ubai Alsharif; Shirina Alsowaidi; Nelson Alvis-Guzman; Erfan Amini; Saeed Amini; Yaw Ampem Amoako; Zohreh Anbari; Nahla Hamed Anber; Catalina Liliana Andrei; Mina Anjomshoa; Fereshteh Ansari; Ansariadi Ansariadi; Seth Christopher Yaw Appiah; Morteza Arab-Zozani; Jalal Arabloo; Zohreh Arefi; Olatunde Aremu; Habtamu Abera Areri; Al Artaman; Hamid Asayesh; Ephrem Tsegay Asfaw; Alebachew Fasil Ashagre; Reza Assadi; Bahar Ataeinia; Hagos Tasew Atalay; Zerihun Ataro; Suleman Atique; Marcel Ausloos; Leticia Avila-Burgos; Euripide F G A Avokpaho; Ashish Awasthi; Nefsu Awoke; Beatriz Paulina Ayala Quintanilla; Martin Amogre Ayanore; Henok Tadesse Ayele; Ebrahim Babaee; Umar Bacha; Alaa Badawi; Mojtaba Bagherzadeh; Eleni Bagli; Senthilkumar Balakrishnan; Abbas Balouchi; Till Winfried Bärnighausen; Robert J Battista; Masoud Behzadifar; Meysam Behzadifar; Bayu Begashaw Bekele; Yared Belete Belay; Yaschilal Muche Belayneh; Kathleen Kim Sachiko Berfield; Adugnaw Berhane; Eduardo Bernabe; Mircea Beuran; Nickhill Bhakta; Krittika Bhattacharyya; Belete Biadgo; Ali Bijani; Muhammad Shahdaat Bin Sayeed; Charles Birungi; Catherine Bisignano; Helen Bitew; Tone Bjørge; Archie Bleyer; Kassawmar Angaw Bogale; Hunduma Amensisa Bojia; Antonio M Borzì; Cristina Bosetti; Ibrahim R Bou-Orm; Hermann Brenner; Jerry D Brewer; Andrey Nikolaevich Briko; Nikolay Ivanovich Briko; Maria Teresa Bustamante-Teixeira; Zahid A Butt; Giulia Carreras; Juan J Carrero; Félix Carvalho; Clara Castro; Franz Castro; Ferrán Catalá-López; Ester Cerin; Yazan Chaiah; Wagaye Fentahun Chanie; Vijay Kumar Chattu; Pankaj Chaturvedi; Neelima Singh Chauhan; Mohammad Chehrazi; Peggy Pei-Chia Chiang; Tesfaye Yitna Chichiabellu; Onyema Greg Chido-Amajuoyi; Odgerel Chimed-Ochir; Jee-Young J Choi; Devasahayam J Christopher; Dinh-Toi Chu; Maria-Magdalena Constantin; Vera M Costa; Emanuele Crocetti; Christopher Stephen Crowe; Maria Paula Curado; Saad M A Dahlawi; Giovanni Damiani; Amira Hamed Darwish; Ahmad Daryani; José das Neves; Feleke Mekonnen Demeke; Asmamaw Bizuneh Demis; Birhanu Wondimeneh Demissie; Gebre Teklemariam Demoz; Edgar Denova-Gutiérrez; Afshin Derakhshani; Kalkidan Solomon Deribe; Rupak Desai; Beruk Berhanu Desalegn; Melaku Desta; Subhojit Dey; Samath Dhamminda Dharmaratne; Meghnath Dhimal; Daniel Diaz; Mesfin Tadese Tadese Dinberu; Shirin Djalalinia; David Teye Doku; Thomas M Drake; Manisha Dubey; Eleonora Dubljanin; Eyasu Ejeta Duken; Hedyeh Ebrahimi; Andem Effiong; Aziz Eftekhari; Iman El Sayed; Maysaa El Sayed Zaki; Shaimaa I El-Jaafary; Ziad El-Khatib; Demelash Abewa Elemineh; Hajer Elkout; Richard G Ellenbogen; Aisha Elsharkawy; Mohammad Hassan Emamian; Daniel Adane Endalew; Aman Yesuf Endries; Babak Eshrati; Ibtihal Fadhil; Vahid Fallah Omrani; Mahbobeh Faramarzi; Mahdieh Abbasalizad Farhangi; Andrea Farioli; Farshad Farzadfar; Netsanet Fentahun; Eduarda Fernandes; Garumma Tolu Feyissa; Irina Filip; Florian Fischer; James L Fisher; Lisa M Force; Masoud Foroutan; Marisa Freitas; Takeshi Fukumoto; Neal D Futran; Silvano Gallus; Fortune Gbetoho Gankpe; Reta Tsegaye Gayesa; Tsegaye Tewelde Gebrehiwot; Gebreamlak Gebremedhn Gebremeskel; Getnet Azeze Gedefaw; Belayneh K Gelaw; Birhanu Geta; Sefonias Getachew; Kebede Embaye Gezae; Mansour Ghafourifard; Alireza Ghajar; Ahmad Ghashghaee; Asadollah Gholamian; Paramjit Singh Gill; Themba T G Ginindza; Alem Girmay; Muluken Gizaw; Ricardo Santiago Gomez; Sameer Vali Gopalani; Giuseppe Gorini; Bárbara Niegia Garcia Goulart; Ayman Grada; Maximiliano Ribeiro Guerra; Andre Luiz Sena Guimaraes; Prakash C Gupta; Rahul Gupta; Kishor Hadkhale; Arvin Haj-Mirzaian; Arya Haj-Mirzaian; Randah R Hamadeh; Samer Hamidi; Lolemo Kelbiso Hanfore; Josep Maria Haro; Milad Hasankhani; Amir Hasanzadeh; Hamid Yimam Hassen; Roderick J Hay; Simon I Hay; Andualem Henok; Nathaniel J Henry; Claudiu Herteliu; Hagos D Hidru; Chi Linh Hoang; Michael K Hole; Praveen Hoogar; Nobuyuki Horita; H Dean Hosgood; Mostafa Hosseini; Mehdi Hosseinzadeh; Mihaela Hostiuc; Sorin Hostiuc; Mowafa Househ; Mohammedaman Mama Hussen; Bogdan Ileanu; Milena D Ilic; Kaire Innos; Seyed Sina Naghibi Irvani; Kufre Robert Iseh; Sheikh Mohammed Shariful Islam; Farhad Islami; Nader Jafari Balalami; Morteza Jafarinia; Leila Jahangiry; Mohammad Ali Jahani; Nader Jahanmehr; Mihajlo Jakovljevic; Spencer L James; Mehdi Javanbakht; Sudha Jayaraman; Sun Ha Jee; Ensiyeh Jenabi; Ravi Prakash Jha; Jost B Jonas; Jitendra Jonnagaddala; Tamas Joo; Suresh Banayya Jungari; Mikk Jürisson; Ali Kabir; Farin Kamangar; André Karch; Narges Karimi; Ansar Karimian; Amir Kasaeian; Gebremicheal Gebreslassie Kasahun; Belete Kassa; Tesfaye Dessale Kassa; Mesfin Wudu Kassaw; Anil Kaul; Peter Njenga Keiyoro; Abraham Getachew Kelbore; Amene Abebe Kerbo; Yousef Saleh Khader; Maryam Khalilarjmandi; Ejaz Ahmad Khan; Gulfaraz Khan; Young-Ho Khang; Khaled Khatab; Amir Khater; Maryam Khayamzadeh; Maryam Khazaee-Pool; Salman Khazaei; Abdullah T Khoja; Mohammad Hossein Khosravi; Jagdish Khubchandani; Neda Kianipour; Daniel Kim; Yun Jin Kim; Adnan Kisa; Sezer Kisa; Katarzyna Kissimova-Skarbek; Hamidreza Komaki; Ai Koyanagi; Kristopher J Krohn; Burcu Kucuk Bicer; Nuworza Kugbey; Vivek Kumar; Desmond Kuupiel; Carlo La Vecchia; Deepesh P Lad; Eyasu Alem Lake; Ayenew Molla Lakew; Dharmesh Kumar Lal; Faris Hasan Lami; Qing Lan; Savita Lasrado; Paolo Lauriola; Jeffrey V Lazarus; James Leigh; Cheru Tesema Leshargie; Yu Liao; Miteku Andualem Limenih; Stefan Listl; Alan D Lopez; Platon D Lopukhov; Raimundas Lunevicius; Mohammed Madadin; Sameh Magdeldin; Hassan Magdy Abd El Razek; Azeem Majeed; Afshin Maleki; Reza Malekzadeh; Ali Manafi; Navid Manafi; Wondimu Ayele Manamo; Morteza Mansourian; Mohammad Ali Mansournia; Lorenzo Giovanni Mantovani; Saman Maroufizadeh; Santi Martini S Martini; Tivani Phosa Mashamba-Thompson; Benjamin Ballard Massenburg; Motswadi Titus Maswabi; Manu Raj Mathur; Colm McAlinden; Martin McKee; Hailemariam Abiy Alemu Meheretu; Ravi Mehrotra; Varshil Mehta; Toni Meier; Yohannes A Melaku; Gebrekiros Gebremichael Meles; Hagazi Gebre Meles; Addisu Melese; Mulugeta Melku; Peter T N Memiah; Walter Mendoza; Ritesh G Menezes; Shahin Merat; Tuomo J Meretoja; Tomislav Mestrovic; Bartosz Miazgowski; Tomasz Miazgowski; Kebadnew Mulatu M Mihretie; Ted R Miller; Edward J Mills; Seyed Mostafa Mir; Hamed Mirzaei; Hamid Reza Mirzaei; Rashmi Mishra; Babak Moazen; Dara K Mohammad; Karzan Abdulmuhsin Mohammad; Yousef Mohammad; Aso Mohammad Darwesh; Abolfazl Mohammadbeigi; Hiwa Mohammadi; Moslem Mohammadi; Mahdi Mohammadian; Abdollah Mohammadian-Hafshejani; Milad Mohammadoo-Khorasani; Reza Mohammadpourhodki; Ammas Siraj Mohammed; Jemal Abdu Mohammed; Shafiu Mohammed; Farnam Mohebi; Ali H Mokdad; Lorenzo Monasta; Yoshan Moodley; Mahmood Moosazadeh; Maryam Moossavi; Ghobad Moradi; Mohammad Moradi-Joo; Maziar Moradi-Lakeh; Farhad Moradpour; Lidia Morawska; Joana Morgado-da-Costa; Naho Morisaki; Shane Douglas Morrison; Abbas Mosapour; Seyyed Meysam Mousavi; Achenef Asmamaw Muche; Oumer Sada S Muhammed; Jonah Musa; Ashraf F Nabhan; Mehdi Naderi; Ahamarshan Jayaraman Nagarajan; Gabriele Nagel; Azin Nahvijou; Gurudatta Naik; Farid Najafi; Luigi Naldi; Hae Sung Nam; Naser Nasiri; Javad Nazari; Ionut Negoi; Subas Neupane; Polly A Newcomb; Haruna Asura Nggada; Josephine W Ngunjiri; Cuong Tat Nguyen; Leila Nikniaz; Dina Nur Anggraini Ningrum; Yirga Legesse Nirayo; Molly R Nixon; Chukwudi A Nnaji; Marzieh Nojomi; Shirin Nosratnejad; Malihe Nourollahpour Shiadeh; Mohammed Suleiman Obsa; Richard Ofori-Asenso; Felix Akpojene Ogbo; In-Hwan Oh; Andrew T Olagunju; Tinuke O Olagunju; Mojisola Morenike Oluwasanu; Abidemi E Omonisi; Obinna E Onwujekwe; Anu Mary Oommen; Eyal Oren; Doris D V Ortega-Altamirano; Erika Ota; Stanislav S Otstavnov; Mayowa Ojo Owolabi; Mahesh P A; Jagadish Rao Padubidri; Smita Pakhale; Amir H Pakpour; Adrian Pana; Eun-Kee Park; Hadi Parsian; Tahereh Pashaei; Shanti Patel; Snehal T Patil; Alyssa Pennini; David M Pereira; Cristiano Piccinelli; Julian David Pillay; Majid Pirestani; Farhad Pishgar; Maarten J Postma; Hadi Pourjafar; Farshad Pourmalek; Akram Pourshams; Swayam Prakash; Narayan Prasad; Mostafa Qorbani; Mohammad Rabiee; Navid Rabiee; Amir Radfar; Alireza Rafiei; Fakher Rahim; Mahdi Rahimi; Muhammad Aziz Rahman; Fatemeh Rajati; Saleem M Rana; Samira Raoofi; Goura Kishor Rath; David Laith Rawaf; Salman Rawaf; Robert C Reiner; Andre M N Renzaho; Nima Rezaei; Aziz Rezapour; Ana Isabel Ribeiro; Daniela Ribeiro; Luca Ronfani; Elias Merdassa Roro; Gholamreza Roshandel; Ali Rostami; Ragy Safwat Saad; Parisa Sabbagh; Siamak Sabour; Basema Saddik; Saeid Safiri; Amirhossein Sahebkar; Mohammad Reza Salahshoor; Farkhonde Salehi; Hosni Salem; Marwa Rashad Salem; Hamideh Salimzadeh; Joshua A Salomon; Abdallah M Samy; Juan Sanabria; Milena M Santric Milicevic; Benn Sartorius; Arash Sarveazad; Brijesh Sathian; Maheswar Satpathy; Miloje Savic; Monika Sawhney; Mehdi Sayyah; Ione J C Schneider; Ben Schöttker; Mario Sekerija; Sadaf G Sepanlou; Masood Sepehrimanesh; Seyedmojtaba Seyedmousavi; Faramarz Shaahmadi; Hosein Shabaninejad; Mohammad Shahbaz; Masood Ali Shaikh; Amir Shamshirian; Morteza Shamsizadeh; Heidar Sharafi; Zeinab Sharafi; Mehdi Sharif; Ali Sharifi; Hamid Sharifi; Rajesh Sharma; Aziz Sheikh; Reza Shirkoohi; Sharvari Rahul Shukla; Si Si; Soraya Siabani; Diego Augusto Santos Silva; Dayane Gabriele Alves Silveira; Ambrish Singh; Jasvinder A Singh; Solomon Sisay; Freddy Sitas; Eugène Sobngwi; Moslem Soofi; Joan B Soriano; Vasiliki Stathopoulou; Mu'awiyyah Babale Sufiyan; Rafael Tabarés-Seisdedos; Takahiro Tabuchi; Ken Takahashi; Omid Reza Tamtaji; Mohammed Rasoul Tarawneh; Segen Gebremeskel Tassew; Parvaneh Taymoori; Arash Tehrani-Banihashemi; Mohamad-Hani Temsah; Omar Temsah; Berhe Etsay Tesfay; Fisaha Haile Tesfay; Manaye Yihune Teshale; Gizachew Assefa Tessema; Subash Thapa; Kenean Getaneh Tlaye; Roman Topor-Madry; Marcos Roberto Tovani-Palone; Eugenio Traini; Bach Xuan Tran; Khanh Bao Tran; Afewerki Gebremeskel Tsadik; Irfan Ullah; Olalekan A Uthman; Marco Vacante; Maryam Vaezi; Patricia Varona Pérez; Yousef Veisani; Simone Vidale; Francesco S Violante; Vasily Vlassov; Stein Emil Vollset; Theo Vos; Kia Vosoughi; Giang Thu Vu; Isidora S Vujcic; Henry Wabinga; Tesfahun Mulatu Wachamo; Fasil Shiferaw Wagnew; Yasir Waheed; Fitsum Weldegebreal; Girmay Teklay Weldesamuel; Tissa Wijeratne; Dawit Zewdu Wondafrash; Tewodros Eshete Wonde; Adam Belay Wondmieneh; Hailemariam Mekonnen Workie; Rajaram Yadav; Abbas Yadegar; Ali Yadollahpour; Mehdi Yaseri; Vahid Yazdi-Feyzabadi; Alex Yeshaneh; Mohammed Ahmed Yimam; Ebrahim M Yimer; Engida Yisma; Naohiro Yonemoto; Mustafa Z Younis; Bahman Yousefi; Mahmoud Yousefifard; Chuanhua Yu; Erfan Zabeh; Vesna Zadnik; Telma Zahirian Moghadam; Zoubida Zaidi; Mohammad Zamani; Hamed Zandian; Alireza Zangeneh; Leila Zaki; Kazem Zendehdel; Zerihun Menlkalew Zenebe; Taye Abuhay Zewale; Arash Ziapour; Sanjay Zodpey; Christopher J L Murray
Journal:  JAMA Oncol       Date:  2019-12-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.